This document provides a detailed stock report on Moderna Inc (MRNA) dated August 19th, 2022. It summarizes Moderna's business operations, key financial metrics, stock performance, analyst ratings, and compares these factors to its industry peers. The report highlights both positive factors like Moderna's earnings and revenue growth, as well as risks like its high stock volatility and valuations. Overall, the report takes a bullish view of Moderna's stock.

1. Page 1 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
MRNA:NSD (Moderna Inc)
Biotechnology | NSD | Common Stock
Values as of 18th Aug, 2022
Stock Target Advisor
Detailed Stock Report
Report Date: 19th August, 2022
Last Close
USD 150.00
Change
-8.00(-5.06%)
Market Cap
USD 65.71B
1 Yr Capital Gain
-60.06%
1 Yr Dividend Return
N/A
1 Yr Total
Return
-60.06%
Earning Growth (5 yr)
5,743.56%
Average Target Price
150.93(+0.62% )
Average Analyst
Rating
Under-perform
Fundamental
Analysis
Bullish
Our view of the stock is Bullish with a score of 7.1 out of 10, where 0 is very bearish and 10 very bullish
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in
the long run.
What to not like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering
to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are
considering to buy.

2. Page 2 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
MRNA:NSD (Moderna Inc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 19th August, 2022
Adjusted Closing Share Volume
Relative Returns Relative Performance (Total Returns)
Security Capital Gain Dividend Return Total Return
MRNA
Moderna Inc
-62.4% 0 -62.4%
QQQ
Invesco QQQ Trust
-9.1% +0.4% -8.7%
Company Overview
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the
treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States,
Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3
vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-
zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell
surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology
products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC;
Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi,
Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life
Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici
S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna,
Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

3. Page 3 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
Company Website
https://www.modernatx.com
Address
200 Technology Square, Cambridge, MA, United States, 02139
Fiscal Year End
December
Employees
3400
Technical Indicators
Value Value
Beta 1.60 52 Week High 464.85
Short Ratio 3.30 52 Week Low 115.61
Shorted Shares 14,731,988 200 Day Moving Average 183.34
Shorted Shares Previous Month 16,288,330 50 Day Moving Average 157.18
Shares Held By Insiders 955.80% Short Percentage 4.00%
Shares Held by Institutions 64.05 Dividend Yield N/A

4. Page 4 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
MRNA:NSD (Moderna Inc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 19th August, 2022
Market Performance
Market Performance vs. Industry / Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
Value Sector Median
Percentile
Rank
Grade Market Median Percentile Rank Grade
YTD
Capital Gain -40.94% -36.4% 43% -15.3% 29%
Dividend Return N/A 6.0% N/A 1.4% N/A
Total Return -40.94% -36.4% 43% -14.2% 29%
Trailing 12 Months
Capital Gain -60.06% -50.0% 40% -15.3% 23%
Dividend Return N/A 8.5% N/A 2.4% N/A
Total Return -60.06% -50.0% 40% -13.6% 23%
Trailing 5 Years
Capital Gain 52,001.42% -50.1% 100% 11.3% 99%
Dividend Return N/A 16.7% N/A 11.0% N/A
Total Return 52,001.42% -49.5% 100% 21.3% 99%
Average Annual (5 Year Horizon)
Capital Gain 688.29% -1.5% 98% 0.4% 99%
Dividend Return N/A 3.0% N/A 1.8% N/A
Total Return 688.29% -1.2% 98% 1.8% 99%
Risk Return Profile
Volatility (Standard
Deviation)
1,009.50% 54.8% 3% 32.7% 2%
Risk Adjusted Return 68.18% N/A 96% 14.5% 92%
Market Capitalization 65.71B 0.15B 100% 0.35B 99%

5. Page 5 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
Key Financial Ratios
Ratios vs. Industry / Classification (Computer Hardware) Ratios vs. Exchange (Nasdaq Global Select)
Value Sector Median
Percentile
Rank
Grade Market Median Percentile Rank Grade
Market Value
peratio 5.0 7.8 55% 16.9 85%
pbratio 3.8 2.4 33% 1.8 26%
pcfratio 4.8 -3.2 7% -0.2 40%
pfcfratio 3.8 -1.2 7% 0.5 43%
Management Effectiveness
retequity 113.86% -59.5% 99% -1.0% 99%
retinvcap 146.21% -53.7% 98% -0.5% 98%
retass 46.34% -26.4% 100% -0.2% 100%
debtequityratio N/A 20.2% N/A 32.4% N/A
Technical Ratios
yield N/A 1.3% N/A 2.6% N/A
sratio 3.30 4.54 60% 3.66 53%
spercent 5.08% 3.9% 41% 2.8% 33%
beta 1.60 1.27 29% 1.07 20%

6. Page 6 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
MRNA:NSD (Moderna Inc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 19th August, 2022
Recent Analyst Ratings
Price Action Rating Action Analyst Rating Price date
Maintains Morgan Stanley Equal-Weight USD 199 » USD 197 2022-08-04
Maintains SVB Leerink Underperform USD 77 » USD 74 2022-08-04
Maintains STA Research Underperform USD 70 2022-07-20
Raised Jefferies Financial LLC USD 170 2022-07-19
Maintains SVB Leerink Underperform USD 80 » USD 70 2022-06-07
Downgrades STA Research Underperform 2022-05-18
Target Down Piper Sandler Overweight USD 214 2022-05-18
Target Raised by Morgan Stanley Equal Weight USD 205 » USD 217 2022-04-12
Target Lowered by SVB Leerink Underperform USD 81 » USD 80 2022-03-25
Target Lowered by Deutsche Bank Capital Hold USD 175 » USD 155 2022-03-07
Maintains Morgan Stanley Equal-Weight USD 213 » USD 205 2022-02-28
Maintains SVB Leerink Underperform USD 85 » USD 81 2022-02-25
Target Lowered by Barclays USD 404 » USD 210 2022-02-25
Target Lowered by Jefferies Financial LLC Hold USD 200 » USD 170 2022-02-25
Downgrade STA Research Buy USD 300 » USD 200 2022-02-24
Maintains Morgan Stanley Equal-Weight USD 315 » USD 213 2022-02-01
Upgraded by Redburn Partners Sell » Neutral 2022-02-01
Maintains SVB Leerink Underperform USD 86 » USD 85 2022-01-28
Upgrades Deutsche Bank Capital Hold USD 175 2022-01-26
Initiates Coverage On UBS Neutral USD 221 2022-01-21
Upgrades Bank of America Securities Neutral USD 135 » USD 180 2022-01-21
Target Raised by Morgan Stanley Equal Weight USD 313 » USD 315 2022-01-18
Target Lowered by Argus USD 420 » USD 350 2022-01-06
Initiates Coverage On Cowen Market Perform USD 250 2021-12-07
Assigns STA Research Strong Buy USD 300 2021-11-15

7. Page 7 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
MRNA:NSD (Moderna Inc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 19th August, 2022
Annual Financial (USD)

8. Page 8 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
MRNA:NSD (Moderna Inc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 19th August, 2022
Quarterly Financial (USD)

9. Page 9 of 9 Any information in this report is not , and should not be regarded as investment advice or as a recommendation regarding any particular security or course of
action. We recommend seeking a licensed professional for investment advice.
MRNA:NSD (Moderna Inc)
Biotechnology | | Common Stock
Stock Target Advisor
Detailed Stock Report
Report Date: 19th August, 2022
Largest Industry Peers for Biotechnology
Symbol Company Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc -4.94 (-1.7%) USD 76.74B
REGN Regeneron Pharmaceuticals Inc -11.51 (-1.8%) USD 70.47B
ALXN Alexion Pharmaceuticals Inc N/A USD 40.34B
BNTX BioNTech SE -4.43 (-2.9%) USD 39.98B
SGEN Seagen Inc -1.70 (-1.0%) USD 31.50B
ALNY Alnylam Pharmaceuticals Inc +0.32 (+0.1%) USD 26.91B
GMAB Genmab AS -0.34 (-0.9%) USD 24.32B
ARGX argenx NV ADR -5.12 (-1.3%) USD 21.45B
IMMU Immunomedics, Inc N/A USD 20.31B
BGNE BeiGene Ltd -1.99 (-1.1%) USD 19.47B
ETFs Containing MRNA
Symbol Company Name Weight Mer Price(Change) Market Cap
QBTL:CA AGFiQ US Market Neutral Anti-B.. 0.21 % 0.00 % +0.37 (+-1.2%) USD 0.24B
BBH VanEck Biotech ETF 0.00 % 0.35 % -2.24 (-1.2%) USD 0.47B
IDNA iShares Genomics Immunology an.. 0.00 % 0.00 % -0.62 (-1.2%) USD 0.21B
QQEQ:CA Invesco NASDAQ 100 Equal Weigh.. 0.00 % 0.00 % N/A N/A
BBIG:CA Horizons Global BBIG Technolog.. 0.00 % 0.00 % +0.07 (+-1.2%) N/A
FHH-F:CA First Trust AlphaDEX U.S. Heal.. 0.00 % 0.00 % N/A N/A
TECB iShares U.S. Tech Breakthrough.. 0.00 % 0.00 % +0.04 (+-1.2%) N/A
GERM ETFMG Treatments Testing and A.. 0.00 % 0.00 % -0.41 (-1.2%) N/A
ZINN:CA BMO MSCI Innovation Index ETF 0.00 % 0.00 % -0.35 (-1.2%) N/A
FTGU:XETRA First Trust US Large Cap Core .. 0.00 % 0.00 % +0.56 (+-1.2%) USD 0.10B
The Stock Target Advisor platform run millions of calculations every day on over 30,000 Canadian and American stocks, comparing and
ranking their financial and market performance against their sectors and exchange.
We represent the percentile ranking using the following grading system.
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%